PURPOSE: Pluronic block copolymers are potent sensitizers of multi-drug resistant (MDR) cancer cells. The sensitization effect by Pluronics is a result of two processes acting in concert: i) intracellular ATP depletion, and ii) inhibition of ATPase activity of drug efflux proteins. This work characterizes effects of Pluronic P85 on ATPase activities of Pgp, MRP1, and MRP2 drug efflux transport proteins and interaction of these proteins with their substrates, vinblastine, and leucotriene C4. METHODS: Using membranes overexpressing Pgp, MRP1, and MRP2, the current study evaluates effects of Pluronic P85 (P85) on the kinetic parameters (Vmax, Km, Vmax/Km) of ATP hydrolysis by these ATPases. RESULTS: The decreases in the maximal reaction rates (Vmax) and increases in apparent Michaelis constants (Km) for these transporters in the presence of various concentrations of P85 were observed. The mechanism of these effects may involve i) conformational changes of the transporter due to membrane fluidization and/or ii) nonspecific steric hindrance of the drug-binding sites by P85 chains embedded into cellular membranes. The extent of these alterations was increased in the row MRP1 < MRP2 << Pgp. CONCLUSIONS: These data suggest that there are unifying pathways for the inhibition of Pgp and MRPs by the block copolymer. However, the effect of P85 on Pgp ATPase activity is considerably greater compared with the effects on MRP1 and MRP2 ATPases. This may be a reason for greater inhibitory effects of Pluronic in Pgp- compared with MRP-overexpressing cells.
PURPOSE:Pluronic block copolymers are potent sensitizers of multi-drug resistant (MDR) cancer cells. The sensitization effect by Pluronics is a result of two processes acting in concert: i) intracellular ATP depletion, and ii) inhibition of ATPase activity of drug efflux proteins. This work characterizes effects of PluronicP85 on ATPase activities of Pgp, MRP1, and MRP2 drug efflux transport proteins and interaction of these proteins with their substrates, vinblastine, and leucotriene C4. METHODS: Using membranes overexpressing Pgp, MRP1, and MRP2, the current study evaluates effects of PluronicP85 (P85) on the kinetic parameters (Vmax, Km, Vmax/Km) of ATP hydrolysis by these ATPases. RESULTS: The decreases in the maximal reaction rates (Vmax) and increases in apparent Michaelis constants (Km) for these transporters in the presence of various concentrations of P85 were observed. The mechanism of these effects may involve i) conformational changes of the transporter due to membrane fluidization and/or ii) nonspecific steric hindrance of the drug-binding sites by P85 chains embedded into cellular membranes. The extent of these alterations was increased in the row MRP1 < MRP2 << Pgp. CONCLUSIONS: These data suggest that there are unifying pathways for the inhibition of Pgp and MRPs by the block copolymer. However, the effect of P85 on Pgp ATPase activity is considerably greater compared with the effects on MRP1 and MRP2 ATPases. This may be a reason for greater inhibitory effects of Pluronic in Pgp- compared with MRP-overexpressing cells.
Authors: Cheol Hee Choi; Kyung Hoon Sun; Chun San An; Jin Cheol Yoo; Kyung Soo Hahm; In Hwa Lee; Jae Kyung Sohng; Youn Chul Kim Journal: Biochem Biophys Res Commun Date: 2002-07-26 Impact factor: 3.575
Authors: Elena V Batrakova; Shu Li; Valery Yu Alakhov; Donald W Miller; Alexander V Kabanov Journal: J Pharmacol Exp Ther Date: 2003-02 Impact factor: 4.030
Authors: Elena V Batrakova; Shu Li; Valery Yu Alakhov; William F Elmquist; Donald W Miller; Alexander V Kabanov Journal: Pharm Res Date: 2003-10 Impact factor: 4.200
Authors: S Danson; D Ferry; V Alakhov; J Margison; D Kerr; D Jowle; M Brampton; G Halbert; M Ranson Journal: Br J Cancer Date: 2004-06-01 Impact factor: 7.640
Authors: Juan W Valle; Anne Armstrong; Chris Newman; Valery Alakhov; Grzegorz Pietrzynski; Julie Brewer; Sue Campbell; Pippa Corrie; Eric K Rowinsky; Malcolm Ranson Journal: Invest New Drugs Date: 2010-02-24 Impact factor: 3.850
Authors: Xiaobin Zhang; Daria Y Alakhova; Elena V Batrakova; Shu Li; Zhihui Yang; Yili Li; Alexander V Kabanov Journal: J Neuroimmune Pharmacol Date: 2008-08-02 Impact factor: 4.147
Authors: Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang Journal: ACS Nano Date: 2013-12-10 Impact factor: 15.881